Navigation Links
Hospira Announces New Contracts in Effect with Novation for Infusion Pumps, Solutions and Equipment

LAKE FOREST, Ill., Oct. 7 /PRNewswire-FirstCall/ -- Hospira (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today announced that the new national infusion pump and solutions and equipment agreements with Novation became effective Oct. 1, 2010. Novation is the leading healthcare supply contracting company of VHA Inc. and the University HealthSystem Consortium (UHC) and Provista. The contracts provide the members served by Novation with continued access to Hospira infusion pumps, related sets and disposable devices, along with intravenous (I.V.) solutions, nutritionals and drug delivery products. These awards provide Hospira contract access for the first time to the 300 UHC member hospitals. The new agreements are effective for five years.

"The comprehensive nature of Hospira's portfolio provides flexibility to support the diverse needs of the members served by Novation," said Pete Baker, vice president and general manager, Commercial Service Operations, Hospira. "With many hospitals today focused on ensuring access to patient safety technology -- such as medication management infusion pumps with safety software -- Hospira welcomes the opportunity to continue to work with Novation to improve patient care."

The new agreements include Hospira's general infusion medication management technologies, such as the Plum A+™  with Hospira MedNet™ safety software, a proven and scaleable infusion pump system; the technologically advanced Symbiq™ infusion system with built-in Hospira MedNet and the LifeCare PCA™ pump with Hospira MedNet. These contracts also continue to provide Novation with access to Hospira's I.V. solutions and associated portfolio, including the environmentally preferable VisIV™ container. These contracts expand upon the nearly 30-year relationship between Hospira and the Novation group purchasing organization.

About Novation

Founded in 1998, Novation is the leading health care supply contracting company for more than 25,000 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances, and 5,500 members of Provista, LLC, representing 28,000 sites. Novation provides alliance members contract and price management and spend management services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC and Provista members used Novation contracts to purchased nearly $37.8 billion in 2009.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. Learn more at

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the agreements with Novation. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, legal, technological, regulatory and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and subsequent Forms 10-Q, filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira to Host Conference Call for Third-Quarter 2010 Results
2. Hospira Receives TGA Approval for Nivestim™, Australias First Biosimilar Filgrastim
3. Hospira Japan Receives Approval for New Indication for Precedex IV™ 200ug
4. Hospira Announces CEO Succession Plan
5. Hospira to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference Aug. 12
6. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
7. Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections
8. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
9. Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.)
10. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
11. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
Post Your Comments:
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group ... a contact channel benchmarking study. Be a part of this insightful ... for improving customer experience, customer journey, contact channel execution and intelligence, workforce optimization, ...
(Date:10/12/2015)... ... ... Holcomb – Kreithen Plastic Surgery and MedSpa, PLLC (“Holcomb – Kreithen”), one of ... Surgery University,” an educational series of mini seminars covering aesthetic and plastic surgery options, ... Saturday, October 24, 2015. , The goal of the event is to provide hands-on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Asthma and ... Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) for a new project ... , The project, entitled “Training Patients with Asthma to Understand and Participate in ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law firm Greenberg ... with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported to be ... ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness program. ...
Breaking Medicine News(10 mins):